Medicare pays $1,938.01 per EsoGuard test as PAVmed's Veris nears its 510(k)

What happened

PAVmed's preliminary third-quarter update, dated 13 November, says its subsidiary Lucid Diagnostics has been paid by Medicare since October. A day earlier, Lucid said Medicare is paying EsoGuard claims at $1,938.01 per test, the full fee schedule rate. Lucid also reported record October test volume. The records give no volume figure, so the scale of the increase is unknown.

The same PAVmed update covers Veris Health, which has frozen its monitor design and started an animal study ahead of an FDA 510(k) submission planned for early 2027. A design freeze generally means the device configuration is fixed before the testing that supports a premarket filing. The records do not say what the animal study is meant to show, or what the monitor is cleared to do, because no clearance has been sought yet.

Why the payment detail matters more than the headline

The headline is that Medicare is paying. The conditions around it matter more to market access teams. Lucid says coverage is being granted case by case while a wider MolDX reconsideration remains pending. MolDX is the Medicare program that assesses coverage for molecular diagnostic tests. Case-by-case coverage differs from a settled national or regional policy. Each claim can depend on individual review, and the outcome of the pending reconsideration could change the picture.

The $1,938.01 rate is a real data point for anyone benchmarking diagnostic pricing. But a full-rate payment does not tell us how many claims are being paid, how many are denied, or how long payment takes. The records say none of this. Payment since October is a start, not evidence of a durable reimbursement position.

Veris: a device pathway that has yet to meet payers

Veris sits at a much earlier stage. A 510(k) is a premarket notification in which a manufacturer shows FDA that its device is substantially equivalent to a legally marketed device. Until the submission is made and reviewed, nothing can be said about clearance timing or indication wording. The records set out only the early-2027 target and the two milestones reached so far.

For market access teams, the lesson from the Lucid side is that reimbursement work is slow and runs alongside regulatory work. Lucid's case-by-case coverage and pending reconsideration show that a product on the market can still lack a stable coverage position. Any payer evidence plan for a device like Veris would need to start before clearance.

The European contrast: access problems begin with supply and compliance

The Danish Medicines Agency's notices of 13 November show a different kind of access barrier. Production or quality problems are behind several of them. Laboratoires Thea's Voltabak (diclofenac) eye drops face a shortage now expected to run to mid-May 2027, with foreign packs allowed under section 29(2) of the Medicines Act. Sandoz production problems are disrupting Vivelle Dot 37.5 micrograms/24 hours patches, with a shortage expected until the end of December. DKMA has also revised the expected import window for a foreign estradiol 25 micrograms/24 hours patch, though the records do not give the new dates.

More final is the Methergin 0.2 mg/ml injection. Essential Pharma Limited has permanently stopped marketing it in Denmark from early November 2026, citing production problems.

On the device side, the Dutch inspectorate IGJ has published a field safety notice from Intersurgical after reports of soft connectors detaching from Smoothbore tubes in sterile and non-sterile breathing systems. Slovakia's ŠÚKL has cancelled the original deadlines for matching EUDAMED data with its national device database. It has said further steps will follow in a separate document, whose content is not in the records. IGJ also published a report on a July 2026 inspection of Maddox Pharma Swiss in Leiden. The available description states no findings, so no conclusion should be drawn from it.

These items are not connected to PAVmed or Lucid. Together they show that US diagnostics teams are waiting on payer decisions, while European teams are managing supply, quality and registry obligations.

What to watch

The first item is the MolDX reconsideration, since its outcome will determine whether case-by-case coverage becomes something firmer. The second is whether Lucid keeps getting paid at the full rate as volume grows. The third is whether Veris files its 510(k) in early 2027 as planned, and what the filing says about intended use. In Denmark, watch the Voltabak and Vivelle Dot dates, since both are expected-end estimates that DKMA has already updated. None of these outcomes is known yet.